共查询到20条相似文献,搜索用时 15 毫秒
1.
Li-Xin Qiu Hui Yuan Ke-Da Yu Chen Mao Bo Chen Ping Zhan Kai Xue Jian Zhang Xi-Chun Hu 《Breast cancer research and treatment》2010,121(3):703-708
Published data on the association between present/null polymorphism of glutathione S-transferase M1 (GSTM1) and breast cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Medline, PubMed, Embase, and Web of Science were searched. Crude ORs with 95% CIs were used to assess the strength of association between the GSTM1 present/null polymorphism and breast cancer risk. The pooled ORs were performed for null versus present genotype. A total of 59 studies including 20,993 cases and 25,288 controls were involved in this meta-analysis. Overall, significantly elevated breast cancer risk was associated with null genotype when all studies were pooled into the meta-analysis (OR = 1.10, 95% CI = 1.04–1.16). In the subgroup analysis by ethnicity, significantly increased risks were found for Caucasians (OR = 1.05, 95% CI = 1.00–1.10) and Asians (OR = 1.21, 95% CI = 1.08–1.35). When stratified by population-based studies or hospital-based studies, statistically significantly elevated risks were found among population-based studies (OR = 1.11, 95% CI = 1.03–1.20). In the subgroup analysis by menopausal status, statistically significantly increased risks were found among postmenopausal women (OR = 1.15, 95% CI = 1.04–1.28). In conclusion, this meta-analysis suggests that the GSTM1 null genotype is a low-penetrant risk factor for developing breast cancer. 相似文献
2.
Zhanwei Wang Hairong Dong Yuanyuan Fu Haixia Ding 《Breast cancer research and treatment》2010,124(3):765-769
RAD51 plays a key role in homologous recombination repair of double-stranded DNA breaks which may cause chromosomal breaks
and genomic instability. We performed a meta-analysis of 9 epidemiological studies involving 13,241 cases and 13,203 controls
that examined the association between RAD51 135G>C polymorphism and breast cancer. No significant association of RAD51 135G>C
polymorphism with breast cancer was found in overall and European populations. However, after the studies which did not fulfill
Hardy–Weinberg equilibrium were excluded, we observed an overall significant increased breast cancer risk (for the recessive
model CC vs. GG/CG: OR = 1.35, 95% CI = 1.05–1.74, P
heterogeneity = 0.06). In summary, our meta-analysis suggested the RAD51 135G>C polymorphism may contribute to breast cancer susceptibility. 相似文献
3.
Haiming Sun Jing Bai Feng Chen Yan Jin Yang Yu Lianhong Jin Songbin Fu 《Breast cancer research and treatment》2011,125(1):157-161
Several studies have investigated the associations between RAD51 G135C polymorphism and the susceptibility to breast cancer,
but results have been inconclusive. In order to derive a more precise estimation of the relationship, a meta-analysis was
performed. A total of 17 case control studies, including 12,153 cases and 10,245 controls, were selected. Overall, significant
decreased risk was found for the additive model (OR = 0.995, 95% CI = 0.991–0.998) and dominant model (OR = 0.994, 95% CI = 0.991–0.998).
In the subgroup analysis by ethnicity, statistically significantly decreased risk was found in Asians (additive model: OR = 0.977,
95% CI = 0.954–1.000 and dominant model: OR = 0.981, 95% CI = 0.963–1.000). In conclusion, this meta-analysis suggests that
the RAD51 G135C polymorphism is a low-penetrant risk factor for developing breast cancer. 相似文献
4.
Yanlei Ma Jianjun Yang Peng Zhang Zhihua Liu Zhe Yang Huanlong Qin 《Breast cancer research and treatment》2011,125(1):237-241
Epidemiological studies have investigated the association between HER2 codon 655 polymorphism and breast cancer susceptibility.
However, the results are still inconclusive. To obtain a more precise estimation of the relationship, this meta-analysis was
performed. A total of 22 studies including 9,209 cases and 10,132 controls were collected. The strength of association between
HER2 codon 655 polymorphism and breast cancer susceptibility was assessed by calculating crude ORs with 95% CIs. When all
the 22 studies were pooled into the meta-analysis, there was no evidence for significant association between HER2 codon 655
polymorphism and breast cancer susceptibility (for Val/Ile vs. Ile/Ile: OR = 1.069, 95% CI = 0.976–1.172; for Val/Val vs.
Ile/Ile: OR = 1.191, 95% CI = 0.922–1.538; for dominant model: OR = 1.093, 95% CI = 0.991–1.206; for recessive model: OR = 1.141,
95% CI = 0.902–1.444). In the subgroup analysis by the source of controls and ethnicity, no significant increased risk was
found in all genetic models. However, the current results indicated the modest association between the HER2 Ile655Val polymorphism
and Asian population (Val/Ile vs. Ile/Ile: OR = 1.207, CI = 1.006–1.450). In summary, the meta-analysis suggests that HER2
codon 655 polymorphism is not associated with the increased breast cancer risk. 相似文献
5.
Li-Xin Qiu Lei Yao Chen Mao Bo Chen Ping Zhan Kai Xue Jian Zhang Hui Yuan Xi-Chun Hu 《Breast cancer research and treatment》2010,123(2):563-567
Published data on the association between TGFB1 L10P polymorphism and breast cancer risk are inconclusive. In order to derive
a more precise estimation of the relationship, a meta-analysis was performed. Crude ORs with 95% CIs were used to assess the
strength of association between them. A total of 30 studies including 20,401 cases and 27,416 controls were involved in this
meta-analysis. Overall, significantly elevated breast cancer risk was associated with TGFB1 10P allele when all studies were
pooled into the meta-analysis (LP vs. LL: OR = 1.046, 95% CI = 1.003–1.090; dominant model: OR = 1.052, 95% CI = 1.012–1.095).
In the subgroup analysis by ethnicity, statistically significantly elevated risk was found in Caucasians (dominant model:
OR = 1.045, 95% CI = 1.001–1.091). When stratified by study design, statistically significantly elevated risk was found based
on population-based studies (dominant model: OR = 1.076, 95% CI = 1.019–1.136). In conclusion, this meta-analysis suggests
that the TGFB1 10P allele may be a low-penetrant risk factor for developing breast cancer. However, large sample and representative
population-based studies with homogeneous breast cancer patients and well-matched controls are warranted to confirm this finding. 相似文献
6.
The A2756G polymorphism in the methionine synthase (MTR) gene has been implicated in breast cancer risk. However, the published
findings are inconsistent. We therefore performed a meta-analysis to investigate this relationship. Eleven published case–control
studies, including 8,438 breast cancer cases and 10,515 controls were identified. Odds ratios (ORs) and 95% confidence intervals
(CIs) were used to assess the strength of the association. Overall, no significant associations between the MTR A2756G polymorphism
and breast cancer risk were found for GG versus AA (OR = 0.98, 95% CI: 0.84–1.15), AG versus AA (OR = 0.95, 95% CI: 0.89–1.01),
GG/AG versus AA (OR = 0.95, 95% CI = 0.89–1.01), and GG versus AG/AA (OR = 1.00, 95% CI: 0.86–1.17). However, in the stratified
analysis, significantly decreased breast cancer risks were found among Europeans (AG versus AA, OR = 0.90, 95% CI = 0.83–0.98;
GG/AG versus AA, OR = 0.90, 95% CI = 0.82–0.97) and studies with population-based controls (AG versus AA, OR = 0.93, 95% CI = 0.86–1.00;
GG/AG versus AA, OR = 0.93, 95% CI = 0.86–1.00). When stratifying by the menopausal status, no significant result was observed
in all genetic models. Taken together, the results suggest that the MTR A2756G polymorphism may contribute to susceptibility
to breast cancer among Europeans. 相似文献
7.
Lin-Bo Gao Xin-Min Pan Hong Sun Xia Wang Li Rao Li-Juan Li Wei-Bo Liang Mei-Li Lv Wen-Zhong Yang Lin Zhang 《Journal of experimental & clinical cancer research : CR》2010,29(1):117
Background
Emerging evidence suggests that ataxia telangiectasia-mutated (ATM) is involved in numerous damage repair signaling pathways and cell-cycle checkpoints. Heterozygous carriers of ATM-mutations have an increased risk for the development of breast cancer. The purpose of this study is to evaluate the association between ATM exon39 5557G > A (D1853N, rs1801516) polymorphism and breast cancer susceptibility with the use of a meta-analysis.Methods
By searching PubMed and Embase databases, a total of 9 epidemiological studies with 4,191 cases and 3,780 controls were identified. Crude odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) for ATM D1853N polymorphism and breast cancer risk were calculated using fixed- or random-effects model based on the degree of heterogeneity among studies.Results
No significant association between the ATM D1853N polymorphism and breast cancer risk was observed in overall analysis (GA versus GG: OR = 1.18; 95% CI, 0.90-1.53; AA versus GG: OR = 0.77; 95% CI, 0.58-1.03; dominant model: OR = 1.16; 95% CI, 0.89-1.51; and recessive model: OR = 0.78; 95% CI, 0.59-1.04, respectively).Conclusion
Our results indicate that ATM D1853N polymorphism is not a risk factor for developing breast cancer. 相似文献8.
Li-Xin Qiu Lei Yao Chen Mao Ke-Da Yu Ping Zhan Bo Chen Hui Yuan Jian Zhang Kai Xue Xi-Chun Hu 《Breast cancer research and treatment》2010,122(2):521-525
Published data on the association between cytochrome P-450 1A2 (CYP1A2)-164 A/C polymorphism and breast cancer risk are inconclusive.
To derive a more precise estimation of the relationship, a meta-analysis was performed. Medline, PubMed, Embase, and Web of
Science were searched. Crude ORs with 95% CIs were used to assess the strength of association between CYP1A2-164 A/C polymorphism
and breast cancer risk. The pooled ORs were performed for co-dominant model (AC versus AA, CC versus AA), dominant model (CC + AC
versus AA), and recessive model (CC versus AA + AC), respectively. A total of 9 studies including 7,580 cases and 10,020 controls
were involved in this meta-analysis. Overall, no significantly elevated breast cancer risk was found in all genetic models
when all studies were pooled into the meta-analysis (AC versus AA: OR = 1.02, 95% CI = 0.92–1.13; CC versus AA: OR = 1.17,
95% CI = 0.83–1.64; dominant model: OR = 1.07, 95% CI = 0.93–1.23; and recessive model: OR = 1.13, 95% CI = 0.82–1.55). In
the subgroup analysis by ethnicity or source of controls, there was still no significant association detected in all genetic
models. In conclusion, upto date, there is still no enough evidence to indicate the association of CYP1A2-164 A/C polymorphism
and breast cancer development. 相似文献
9.
Cyclin D1 (CCND1) plays an essential role in tumor development and progression through regulating the cell transition from G1 to the proliferative S phase. The CCND1 G870A polymorphism has been associated with an increased susceptibility to squamous cell carcinoma of the head and neck, bladder, prostate, and gastric cardiac cancers. There are a number of studies that explored the relationship between CCND1 G870A polymorphism and breast cancer risk, with inconsistent conclusions. In order to better define the predictive value of CCND1 G870A polymorphism in breast cancer, we searched PubMed and EBSCO for relevant publications. A total of 13 studies were indentified, which included 11,235 cases and 12,763 controls. We calculated the summary odds ratios and the corresponding 95% confidence interval. Our meta-analysis showed that carriers of AA genotype have a significantly higher risk in developing breast cancer compared with that of GG genotype (OR = 1.08, 95% CI = 1.01-1.17, p > = 0.03) in overall population. Furthermore, in subgroup analysis, CCND1 G870A polymorphism was associated with a marginally increased risk of breast cancer for Chinese compared to Caucasian populations with an OR = 1.14, 95% CI = 1.00-1.20, p-trend = 0.06 for AA + GA versus GG, if the controls were hospital-based population with an OR = 1.21, 95% CI = 0.99-1.47, p = 0.06 for AA versus GG and if the distributions of genotypes in control groups were consistent with the Hardy-Weinberg equilibrium (HWE) with an OR = 1.08, 95% CI = 1.00-1.15, p = 0.04 for AA versus GA + GG. Our meta-analysis represents the largest study to date indicating that the G870A polymorphism in CCND1 confers an increased risk for breast cancer. Further studies are warranted to explore the preventive measures to detect and manage the breast cancers attributable to the G870A polymorphism. 相似文献
10.
Li-Xin Qiu Jian Zhang Xiao-Dong Zhu Chun-Lei Zheng Si Sun Zhong-Hua Wang Xin-Min Zhao Jia-Lei Wang Lei-Ping Wang Hui Yu Kai Xue Xi-Chun Hu 《Breast cancer research and treatment》2010,124(2):475-479
Published data on the association between p21 Ser31Arg polymorphism and breast cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Crude ORs with 95% CIs were used to assess the strength of association between the p21 Ser31Arg polymorphism and breast cancer risk. The pooled ORs were performed for co-dominant model (Ser/Arg vs. Ser/Ser, Arg/Arg vs. Ser/Ser), dominant model (Arg/Arg + Ser/Arg vs. Ser/Ser), and recessive model (Arg/Arg vs. Ser/Arg + Ser/Ser). A total of 21 studies including 22,109 cases and 29,127 controls were involved in this meta-analysis. Overall, no significant associations were found between p21 Ser31Arg polymorphism and breast cancer risk when all studies pooled into the meta-analysis. In the subgroup analysis by ethnicity, significantly increased risk was found for Caucasians (Arg/Arg vs. Ser/Ser: OR 1.496, 95% CI 1.164–1.924; and recessive model: OR 1.492, 95% CI 1.161–1.919). When stratified by study design, statistically significantly elevated risk was found for population-based studies (Ser/Arg vs. Ser/Ser: OR 1.085, 95% CI 1.019–1.156). In conclusion, this meta-analysis suggests that the p21 Ser31Arg polymorphism may be associated with breast cancer development in Caucasian. However, large sample and representative population-based studies with homogeneous breast cancer patients and well-matched controls are warranted to confirm this finding. 相似文献
11.
Yongsheng Huang Binghui Li Ji Qian Jingtian Xie Long Yu 《Breast cancer research and treatment》2010,123(3):863-868
Transforming growth factor β1 (TGF-β1) is a cytokine, playing an important role in controlling cell proliferation and differentiation
involved in breast cancer. It was reported the 29T/C polymorphism in TGF-β1 has been implicated in breast cancer risk. However,
studies on the association between this polymorphism and breast cancer remain conflicting. To derive a more precise estimation
of the relationship, a meta-analysis of 10,341 cases and 15,655 controls from fifty published case-control studies was performed.
Our analysis suggested that 29T/C has no association with a trend of breast cancer risk when using both dominant [odds ratio
(OR) = 1.01, 95% confidence intervals (CI) 0.96–1.07] and recessive models (OR = 0.98, 95% CI 0.89–1.08) to analyze the data.
In ethnic subgroups analysis, 29T/C also did not appear to be risk factors for breast cancer. However, larger scale primary
studies are required to further evaluate the interaction of TGF-β1 29T/C polymorphism and breast cancer risk in specific populations. 相似文献
12.
Su Lu Zhanwei Wang Dan Cui Hong Liu Xishan Hao 《Breast cancer research and treatment》2011,125(1):253-259
Glutathione S-transferase P1 (GSTP1) is involved in a wide range of detoxifying reactions. Any alteration in the structure,
function, or expression of GSTP1 gene may alter the ability of a cell to inactivate carcinogens or mutagens, and thus modify
an individual’s risk to cancer. Previous epidemiological studies on the potential association between GSTP1 Ile105Val polymorphism
and breast cancer risk have produced inconsistent results. In order to drive a more precise estimation of this association,
we performed a meta-analysis of 30 published case–control studies including 15,901 cases and 18,757 controls. Crude odds ratios
(ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association. The results of this meta-analysis
showed that GSTP1 Ile105Val polymorphism was not associated with breast cancer susceptibility in overall population. However,
in subgroup analysis by ethnicity, we found a significant association among Asian population (for Val/Val vs. Ile/Ile: OR
1.27, 95% CI 1.02–1.83; for the recessive model Val/Val vs. Ile/Ile + Ile/Val: OR 1.42, 95% CI 1.20–1.69). When stratified
by study design, significantly elevated susceptibility to breast cancer was found among hospital-based studies (for Val/Val
vs. Ile/Ile: OR 1.38, 95% CI 1.16–1.63; for recessive model Val/Val vs. Ile/Val + Ile/Ile: OR 1.31, 95% CI 1.12–1.55; for
dominant model: Val/Val + Ile/Val vs. Ile/Ile: OR 1.10, 95% CI 1.02–1.19). In conclusion, our meta-analysis suggests that
GSTP1 Ile105Val polymorphism may increase susceptibility to breast cancer in Asian population. 相似文献
13.
Yiyi Sun Zhihe Zang Xiaohong Xu Zhonglin Zhang Ling Zhong Wang Zan Yan Zhao Lin Sun 《Breast cancer research and treatment》2011,125(1):215-219
Epidemiological studies on the association between SULT1A1 codon 213 polymorphism and breast cancer risk are inconclusive.
In order to derive a more precise estimation of the association, a meta-analysis was conducted in this article. Sixteen studies
including 9,881 cases and 13,564 controls were collected for SULT1A1 codon 213 polymorphism by searching the databases of
Medline, PubMed, Embase, and ISI Web of Knowledge. The strength of association between SULT1A1 codon 213 polymorphism and
breast cancer susceptibility was assessed by calculating crude ORs with 95% CIs. When all the 21 studies were pooled into
the meta-analysis, there was no evidence for significant association between SULT1A1 codon 213 polymorphism and breast cancer
susceptibility (for Arg/Arg versus Arg/His: OR = 0.999, 95% CI = 0.941–1.061; for Arg/Arg versus His/His: OR = 1.121, 95%
CI = 1.013–1.242; for dominant model: OR = 1.128, 95% CI = 1.01–1.26; for recessive model: OR = 1.151, 95% CI = 0.950–1.394).
In the subgroup analysis by the source of controls, significant increased risk was found for hospital-based studies (for Arg/Arg
versus Arg/His: OR = 1.173, 95% CI = 1.000–1.376; for Arg/Arg versus His/His: OR = 1.600, 95% CI = 1.134–2.256; for dominant
model: OR = 1.269, 95% CI = 1.134–2.256; for recessive model: OR = 1.664, 95% CI = 1.070–2.588). In summary, the meta-analysis
suggests that SULT1A1 codon 213 polymorphism may be associated with the hospital-based studies. However, large number of samples
and representative hospital-based studies with homogeneous breast cancer patients and well-matched controls are warranted
to confirm this finding. 相似文献
14.
Li-Xin Qiu Lei Yao Hui Yuan Chen Mao Bo Chen Ping Zhan Kai Xue Jian Zhang Xi-Chun Hu 《Breast cancer research and treatment》2010,122(3):867-871
Published data on the association between insulin-like growth factor binding protein 3 (IGFBP3) A-202C polymorphism and breast
cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Crude
ORs with 95% CIs were used to assess the strength of association between them. A total of 27 studies including 33,557 cases
and 45,254 controls were involved in this meta-analysis. Overall, significantly elevated breast cancer risk was associated
with IGFBP3 C allele when all studies were pooled into the meta-analysis (CC vs. AA: OR = 1.06, 95% CI = 1.02–1.11; dominant
model: OR = 1.04, 95% CI = 1.00–1.07). In the subgroup analysis by ethnicity, significantly increased risk was found for Caucasians
(AC vs. AA: OR = 1.04, 95% CI = 1.00–1.08; CC vs. AA: OR = 1.05, 95% CI = 1.01–1.10; dominant model: OR = 1.04, 95% CI = 1.00–1.08)
and Asians (CC vs. AA: OR = 1.35, 95% CI = 1.02–1.78; recessive model: OR = 1.38, 95% CI = 1.05–1.82). When stratified by
study design, statistically significantly elevated risk was found among population-based studies (CC vs. AA: OR = 1.06, 95%
CI = 1.01–1.11; dominant model: OR = 1.03, 95% CI = 1.00–1.07). In the subgroup analysis by menopausal status, no statistically
significantly increased risk was found among premenopausal or postmenopausal women. In conclusion, this meta-analysis suggests
that the IGFBP3 C allele is a low-penetrant risk factor for developing breast cancer. 相似文献
15.
Li-Xin Qiu Bo Chen Chen Mao Ping Zhan Hui Yuan Kai Xue Jin Li Xi-Chun Hu 《Breast cancer research and treatment》2009,118(3):599-603
Published data on the association between STK15 F31I polymorphism and breast cancer risk are inconclusive. In order to derive
a more precise estimation of the relationship, a meta-analysis was performed. Medline, PubMed, Embase, Web of Science, and
Chinese Biomedicine Database were searched. Crude ORs with 95% CIs were used to assess the strength of association between
the STK15 F31I polymorphism and breast cancer risk. The pooled ORs were performed for codominant model (FI vs. FF; II vs.
FF), dominant model (FI + II vs. FF), and recessive model (II vs. FI + FF), respectively. A total of 10 studies including
10,537 cases and 14,477 controls were involved in this meta-analysis. Overall, significantly elevated breast cancer risk was
associated with II variant genotype in homozygote comparison and recessive genetic model when all studies were pooled into
the meta-analysis (for II vs. FF: OR = 1.23, 95% CI = 1.10–1.37; for recessive model: OR = 1.21, 95% CI = 1.05–1.40). In the
subgroup analysis by ethnicity, significantly increased risks were found for II allele carriers among Caucasians (for II vs.
FF: OR = 1.24, 95% CI = 1.08–1.43; for recessive model: OR = 1.21, 95% CI = 1.00–1.45); significantly increased risks were
also found among Asians for II versus FF (OR = 1.21; 95% CI = 1.01–1.45). In conclusion, this meta-analysis suggests that
the STK15 31II allele is a low-penetrant risk factor for developing breast cancer. 相似文献
16.
Jian Zhang Li-Xin Qiu Zhong-Hua Wang Xiang-Hua Wu Xiao-Jian Liu Bi-Yun Wang Xi-Chun Hu 《Breast cancer research and treatment》2010,123(2):549-555
Published data on the association between MTHFR C677T polymorphism and breast cancer risk are inconclusive. To derive a more
precise estimation of the relationship, a meta-analysis was performed. Medline, PubMed, Embase, and Web of Science were searched.
Crude ORs with 95% CIs were used to assess the strength of association between the MTHFR C677T polymorphism and breast cancer
risk. The pooled ORs were performed with co-dominant model (CT vs. CC, TT vs. CC), dominant model (CT + TT vs. CC), and recessive
model (TT vs. CC + CT), respectively. A total of 37 studies including 15,260 cases and 20,411 controls were involved in this
meta-analysis. Overall, significantly elevated breast cancer risk was associated with TT variant genotype in homozygote comparison
and dominant genetic model when all studies were pooled into the meta-analysis (TT vs. CC: OR = 1.11, 95% CI = 1.01–1.23;
dominant model: OR = 1.04, 95% CI = 1.00–1.09). In the subgroup analysis by ethnicity, significantly increased risks were
found for TT allele carriers among Asians (TT vs. CC: OR = 1.18, 95% CI = 1.04–1.35; recessive model: OR = 1.15, 95% CI = 1.03–1.29).
When stratified by study design, statistically significantly elevated risk was found in hospital-based studies (TT vs. CC:
OR = 1.18, 95% CI = 1.02–1.38; recessive model: OR = 1.17, 95% CI = 1.05–1.29). In the subgroup analysis by menopausal status,
statistically significantly increased risk was found among postmenopausal women (CT vs. CC: OR = 1.12, 95% CI = 1.02–1.23;
dominant model: OR = 1.11, 95% CI = 1.01–1.22). In conclusion, this meta-analysis suggests that the MTHFR T allele is a low-penetrant
risk factor for developing breast cancer. 相似文献
17.
Li-Xin Qiu Lei Yao Chen Mao Bo Chen Ping Zhan Hui Yuan Kai Xue Jian Zhang Xi-Chun Hu 《Breast cancer research and treatment》2010,123(2):543-547
Published data on the association between MnSOD Val16Ala polymorphism and breast cancer risk are inconclusive. To derive a
more precise estimation of the relationship, a meta-analysis was performed. Medline, PubMed, Embase, and Web of Science were
searched. Crude ORs with 95% CIs were used to assess the strength of association between the MnSOD Val16Ala polymorphism and
breast cancer risk. The pooled ORs were performed for co-dominant model (Val/Ala vs. Val/Val, Ala/Ala vs. Val/Val), dominant
model (Ala/Ala + Val/Ala vs. Val/Val), and recessive model (Ala/Ala vs. Val/Ala + Val/Val), respectively. A total of 32 studies
including 26,022 cases and 32,426 controls were involved in this meta-analysis. Overall, no significant associations were
found between MnSOD Val16Ala polymorphism and breast cancer risk when all studies pooled into the meta-analysis (Val/Ala vs.
Val/Val: OR = 1.022, 95% CI = 0.981–1.064; Ala/Ala vs. Val/Val: OR = 1.006, 95% CI = 0.934–1.083; dominant model: OR = 1.013,
95% CI = 0.962–1.066; and recessive model: OR = 0.985, 95% CI = 0.931–1.042). In the subgroup analysis by ethnicity or study
design, still no significant associations were found for all comparison models. In conclusion, this meta-analysis suggests
that the MnSOD Val16Ala polymorphism may be not associated with breast cancer development. However, large sample and representative
population-based studies with homogeneous breast cancer patients and well-matched controls are warranted to confirm this finding. 相似文献
18.
Lei Yao Fang Fang Qi Wu Zhen Yang Yang Zhong Long Yu 《Breast cancer research and treatment》2010,122(1):221-227
Breast cancer is one of the most common malignant tumors worldwide. To date, many articles have evaluated the association
between Cytochrome P450c17 (CYP17) T-34C polymorphism and breast cancer risk. However, the results remain inconclusive. In
order to derive a more precise estimation of the association, a meta-analysis was performed in this study. By searching Medline,
ISI Web of Knowledge, Cochrane, ScienceDirect, EBSCO, CNKI, and SinoMed databases, 43 studies including 26,008 cases and 32,806
controls were collected for CYP17 T-34C polymorphism. Crude ORs with 95% CIs were used to assess the strength of association
between CYP17 T-34C polymorphism and breast cancer risk. The pooled ORs were performed for codominant model, dominant model,
and recessive model, respectively. Overall, no significant associations between CYP17 T-34C polymorphism and breast cancer
susceptibility were found for TT versus CC (OR = 0.96; 95% CI: 0.89–1.05), TC versus CC (OR = 0.97; 95% CI: 0.89–1.06), TT + TC
versus CC (OR = 0.97; 95% CI: 0.89–1.05) and TT versus TC + CC (OR = 0.98; 95% CI: 0.93–1.03). In the stratified analysis
by ethnicity, menopausal status, and sources of controls, significant associations were still not detected in all genetic
models. In conclusion, this meta-analysis strongly suggests that CYP17 T-34C polymorphism is not associated with breast cancer
risk. 相似文献
19.
Many studies were published to assess the association between FASLG T844C polymorphism and susceptibility to breast cancer, but the data were controversial. A meta-analysis was performed to assess the association comprehensively. We performed a comprehensive search in PubMed, Embase, and Web of Science to find eligible studies. Six studies with a total of 6,784 participants were finally included into the meta-analysis. There were a total of 3,382 cases with breast cancer and 3,402 controls in those six studies. Odds ratio (OR) with 95 % confidence interval (95 %CI) was used to evaluate the association. Overall, there was an obvious association between FASLG T844C polymorphism and breast cancer under all four contrast models (for C versus T: OR?=?1.26, 95 %CI 1.05–1.50, P OR?=?0.011; for CC versus TT: OR?=?1.42, 95 %CI 1.11–1.81, P OR?=?0.005; for CC versus TT/TC: OR?=?1.41, 95 %CI 1.06–1.88, P OR?=?0.019; for CC/TC versus TT: OR?=?1.16, 95 %CI 1.01–1.33, P OR?=?0.038). In the subgroup analysis by ethnicity, there was an obvious association between FASLG T844C polymorphism and breast cancer in Asians, but there was no obvious association in Caucasians. The meta-analysis suggests that there is an association between FASLG T844C polymorphism and susceptibility to breast cancer, especially in Asians. 相似文献
20.
Vitamin D receptor (VDR) principally mediates the anticancer activities of vitamin D. Many studies investigated the association between VDR gene ApaI polymorphism and breast cancer, but the results were inconclusive. We performed this meta-analysis to evaluate the association between VDR gene ApaI polymorphism and breast cancer. Twelve studies with a total of 8,254 subjects were identified from PubMed and Wanfang databases. The pooled odds ratio (OR) and confidence intervals (95 % CI) were used to assess the association. The meta-analysis indicated that VDR gene ApaI polymorphism was not associated with risk of breast cancer (a vs. A: OR?=?0.97, 95 % CI 0.91–1.04, P?=?0.378; aa vs. AA: OR?=?0.97, 95 % CI 0.85–1.10, P?=?0.618; aa vs. AA + Aa: OR?=?1.00, 95 % CI 0.89–1.12, P?=?0.972; aa + Aa vs. AA: OR?=?0.95, 95 % CI 0.82–1.11, P?=?0.550). Subgroup analysis by ethnicity further showed that VDR gene ApaI polymorphism was not associated with risk of breast cancer in both Asians and Caucasians. These data from the meta-analysis indicate that VDR gene ApaI polymorphism is not associated with breast cancer susceptibility. 相似文献